Role of Stabilin receptors in rheumatoid arthritis
Funded at Ohio State University · NIH-11453262 · Data updated 2026-11-12
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 15, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $210,244 |
| NIH project number | 1R21AR086391-01A1 |
| Project ID | NIH-11453262 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with or at risk for rheumatoid arthritis, or individuals with autoimmune disease biology relevant to RA, may benefit from future therapies informed by these findings.
✕Less likely to help
The study itself does not involve patient treatment; only underlying mechanisms are explored, so immediate clinical benefits are not guaranteed.
What this research studies
This project looks at how Stabilin-1 and Stabilin-2 receptors may affect immune cells and inflammatory processes in rheumatoid arthritis. By studying a mouse model of arthritis and analyzing patient synovial tissue data, the researchers aim to identify how these receptors contribute to disease onset and progression. The findings could point to new ways to delay RA or reduce its impact on joints and overall health. The work focuses on immune interactions in the joint environment and in the blood to uncover actionable biology that could guide future therapies.
Why it matters
Potential benefit: If successful, the research could lead to new targets for preventing or slowing rheumatoid arthritis and reducing related health problems.
How similar studies have gone: Prior studies linking scavenger receptors to immune regulation have shown meaningful insights, but the specific role of Stabilin-1/2 in RA is still being clarified.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Ganesan, Latha Prabha — Ohio State University
- Study coordinator: Ganesan, Latha Prabha
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
-
FRAX fracture risk in rheumatoid arthritis patients 65 and older
This grant tests how well the FRAX fracture risk tool predicts fractures in people with rheumatoid arthritis who are 65 and older.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.